Archean Chemical Industries Ltd
NSE:ACI
Archean Chemical Industries Ltd
Archean Chemical Industries Ltd. produces sulphate of potash, gypsum, bromine, and several industrial chemicals through conversion of naturally available marine mineral deposits. The company is headquartered in Chennai, Tamil Nadu and currently employs 265 full-time employees. The company went IPO on 2022-11-21. The firm is engaged in activities related to production and supply of marine chemicals. The company is a producer and exporter of Bromine and Industrial Salt. The firm's portfolio of products also includes Potassium Sulfate (SOP). The firm serves a range of industries, including agriculture, pharmaceutical, water treatment, aluminum, glass, and textiles.
Archean Chemical Industries Ltd. produces sulphate of potash, gypsum, bromine, and several industrial chemicals through conversion of naturally available marine mineral deposits. The company is headquartered in Chennai, Tamil Nadu and currently employs 265 full-time employees. The company went IPO on 2022-11-21. The firm is engaged in activities related to production and supply of marine chemicals. The company is a producer and exporter of Bromine and Industrial Salt. The firm's portfolio of products also includes Potassium Sulfate (SOP). The firm serves a range of industries, including agriculture, pharmaceutical, water treatment, aluminum, glass, and textiles.
Revenue Growth: Archean Chemicals reported 11% year-on-year revenue growth for the 9-month period and around 10–12% growth in Q3 FY '26, with demand in industrial salt and derivatives partly offsetting weakness in bromine.
EBITDA Pressure: Q3 EBITDA declined by 25% year-on-year, with margins at nearly 27%, mainly due to increased logistics, new employee, and overhead costs.
Bromine Strength & Challenges: Bromine demand remains strong with healthy order book, but production has been impacted by operational issues and weather-related disruptions.
Stable Salt Pricing: Industrial salt volumes have rebounded to over 1 million tons per quarter with stable pricing and robust demand.
Derivatives & SOP Delays: Utilization at the derivatives plant remains low (30–40%) with a focus on product development; SOP plant trials are ongoing with meaningful contributions expected only from FY '27.
Strategic Initiatives On Track: Semiconductor and energy storage projects are progressing as planned, though both are in early phases and will take time to contribute.
